Life sciences.
|
|
 |
AIMEDICS |
|
AIMEDICS are the inventors of HypoMon, an effective non-invasive, real-time warning system for the detection of hypoglycaemia (low blood-glucose) in Type I insulin-dependent diabetic patients. Medical and physiological conditions that the technology has applications include diabetes, SIDS, epilepsy and fatigue. |
|
|
|
|
 |
Adventus Technology |
|
Born from the Vision Cooperative Research Centre (Vision CRC), the world’s largest vision correction research centre, Adventus Technology (Australia) Pty. Ltd (“Adventus”) aims to further the development, approval and commercialisation of two new ophthalmic products which have the potential to both revolutionise the global ophthalmic device market and underpin a new era for the more than 50% of the world’s population who need vision correction. |
|
|
|
|
 |
Better Health & Wellness |
|
Better Health & Wellness Solutions has developed a totally natural sweetener that is now available for food manufacturers to use to help in the fight against obesity and make traditionally unhealthy food and beverage products “better for you”. SweeTose is a totally natural protein that tastes sweet and unlike other products on the market, SweeTose has a much lower calorific value and GI rating. The technology has been developed locally in Australia and The Manildra group is the licensed partner for manufacture and distribution of SweeTose for the food and beverage industry. |
|
|
|
|
 |
Biofusion Capital |
|
BioFusion Capital invests in life science opportunities. Particular interest is in linking Australian and Asian technologies, investments and markets. |
|
|
|
|
 |
Bioline |
|
Bioline is a manufacturer of high quality Molecular Biology reagents. Our reagents are widely used in academic institutions, public health laboratories and biotechnology firms enabling DNA and RNA based research. |
|
|
|
|
 |
Bioprocess |
|
Bioprocess develops technologies and owns intellectual property rights pertaining to a proprietary, highly effective E.coli-based vector system designed to accommodate a wide range of gene constructs for high level protein expression, including blood viral key components for use in developing in-vitro diagnostics. |
|
|
|
|
 |
Chemeq Technologies |
|
Chemeq Technologies Pty Ltd has developed and patented a unique anti-microbial polymer providing the human health, personal care, specialized industrial markets and animal health markets with a safe, effective and resistance-free alternative to antibiotics and conventional biocides. |
|
|
|
|
 |
ECOZEAN |
|
ECOZEAN offers a proprietary, cost effective, durable, and easy to apply coating inhibiting the growth of marine fouling on surfaces exposed to, or immersed in the sea. It is non-toxic and environmentally safe. Applications include aquaculture and fisheries, marine access and recreation areas, intake and outfall pipes, as well as a broad range of commercial and industrial environments. |
|
|
|
|
 |
Elastagen |
|
Elastagen is a clinical stage medical device company that is pioneering Elastatherapy™ using the human protein Elastin to naturally repair and augment the skin. |
|
|
|
|
 |
Endoluminal Sciences |
|
Endoluminal Sciences is an early stage venture capital-backed company, committed to the development of novel platform technologies to dramatically enhance the clinical performance of endovascular prostheses. While the technology is foreseen to have its application to a range of vascular disease states, the immediate focus is the treatment of abdominal aortic aneurysms. |
|
|
|
|
 |
Environmental Biotechnology CRC |
|
Environmental Biotechnology Cooperative Research Centre (EBCRC) develops advanced technologies based on biological systems to improve efficiency and reduce or utilise waste to benefit a wide range of industries and the environment. EBCRC concentrates its research and commercial efforts in three core areas: biofilm prevention and dispersal, rapid in-field microbial detection and control and bioprocesses such as bioremediation and industrial wastewater treatment. |
|
|
|
|
 |
EvolveTech |
|
ITL Design & Manufacturing is a full scale industrial design and manufacturing company. Their latest release is the Animal Blood Collection Kit. The Animal Blood Collection Kit helps farmers to safely and efficiently collect blood samples from their livestock, which is then ready to be sent for laboratory testing. |
|
|
|
|
 |
Innovative Purification Technologies |
|
IPT was founded in response to the demand for alternative supply sources of high quality separation media for the industrial biotechnology market. In particular IPT is focusing on developing innovative media for process scale affinity separations designed to outperform existing products currently available. IPT has a number of patent applications covering various aspects of our novel technologies. IPT’s state of the art equipment for protein purification and development of protein purification strategies and procedures includes Äkta Explorers, FPLCs and large scale columns designed for cGMP manufacturing. |
|
|
|
|
 |
PAFtec |
|
We are a developer, manufacturer and marketer of advanced personal respiratory protection devices. Leading the way to a cleaner and healthier future. PAFtec offers the most innovated personal clean air devices for anyone seeking an advanced solution to the filtration of air pollutants in industrial, commercial or residential environments. In a world with a daunting array of air pollutants, allergens and chemicals, PAFtec promises new technology that delivers you cleaner and fresher air to breath – your personal CleanSpace. |
|
|
|
|
 |
NeuClone |
|
NeuClone has developed a robust platform technology for generating commercial cell lines used in the manufacture of therapeutic proteins. The company is using its extensive expertise in cell line engineering to enable its clients to exploit the significant potential of biosimilars. A Biosimilar is an off patent prescription medication that is produced in living organisms using bioproduction processes. There are 45 biologic drugs coming off patent by 2014 with a cumulative worth of US$60B per annum. NeuClone licenses its proprietary cell lines to enable its clients to fast-track the safe and low-cost manufacture of biosimilars. |
|
|
|
|
 |
Stephen Sanig Research Institute |
|
The Stephen Sanig Research Institute builds upon Australia’s outstanding pool of primary medical research and works in collaboration with academic institutions in Australia and overseas to develop industrially viable biopharmaceutical products. Its activities include (i) research & development and the production of biopharmaceutical products, which can be used for the improvement of public health, e.g. inflammatory diseases, cancer, etc.; (ii) educational programs for the public to broaden public awareness and facilitate a better practice for dealing with these health problems. |
|
|
|
|
 |
SpeeDx |
|
SpeeDx Pty Ltd focuses on the development of faster, simpler, cheaper diagnostics. The best outcome for many diseases is linked to early diagnosis. Our technology enables rapid diagnosis of early-stage disease to produce a positive impact on health care worldwide. SpeeDx was founded in 2009 to take advantage of MNAzyme and DNAzyme technology. MNAzymes are inexpensive and stable compounds that can be designed to detect most genetic sequence including cancer biomarkers, viruses and bacteria. This huge versatility, combined with affordable and fast manufacture, makes MNAyzmes ideal tools for robust genetic diagnostics. In addition to applications in the fields of human and veterinary diagnostics, MNAzymes find utility in agriculture and food testing. |
|
|
|
|
 |
TM Ventures |
|
TM Ventures is supporting innovation at all levels of the technology life cycle. With offices in Australia and North America, we facilitate strategic corporate relationships specific to our clients’ needs. We work hand-in-hand with universities, research institutes and technology transfer offices to maximise their return on investment and expand their resource-base. |
|
|
|
|
 |
Vaxine |
|
Vaxine is a vaccine company focused on developing & producing vaccine products for the treatment & prevention of infectious & cancer diseases. The company is commercialising world-class Australian vaccine research based on novel adjuvant technology. Results from a recent phase I clinical trials on a HBV vaccine with this technology have shown a clean safety performance with a strong cell-mediated as well as a humoral response. |
|
|
|
|
“ATP Innovations has been invaluable in exposing us to a network of service providers, investors and company peers – there always seems to be someone we can talk to who has already overcome the next challenge we face”.
Dr Rob Daniels, CEO, Elastagen.
“ATP Innovations is an ideal location for building a technology business. The combination of an extensive network, the camaraderie with other likeminded companies, the location and the ATP Innovations team has all become critical factors in the success of the NeuClone business.”
Dr Noelle-Ann Sunstrom, CEO, Neuclone.
